Rating Rationale
September 20, 2018 | Mumbai
Cadila Healthcare Limited
 
Rating Action
Total Bank Loan Facilities Rated Rs.3577 Crore
Long Term Rating CRISIL AA+/Positive
Short Term Rating CRISIL A1+
 
Rs.125 Crore Non Convertible Debentures CRISIL AA+/Positive
Rs.250 Crore Commercial Paper& CRISIL A1+
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
&Earlier STD (Including CP)
Detailed Rationale

CRISIL's ratings on the bank facilities and debt instruments of Cadila Healthcare Limited (Cadila Healthcare; part of the Zydus Cadila group) continue to reflect the Zydus Cadila group's established position in the branded generics market in India, and its growing presence in the international generics markets, particularly the US. The ratings also factor in a healthy financial risk profile, with sound debt protection metrics and adequate gearing. These strengths are partially offset by exposure to risks related to unfavourable regulatory changes, increasing competition, and price erosions in the regulated generics markets.

On June 29, 2018, CRISIL had revised its outlook on the non-convertible debentures and long-term bank facility of Cadila Healthcare to 'Positive' from 'Stable', while reaffirming the rating at 'CRISIL AA+'.

The outlook revision reflects CRISIL's expectation of stronger revenue growth in regulated markets, accelerated revenue growth from the domestic formulations business in line with larger market growth and sustained healthy financial profile, especially the capital structure.

In fiscal 2018 and first quarter of fiscal 2019, revenue grew over 25%, largely led by the US segment; growth was driven by an exclusive opportunity in mesalamine (generic version of Lialda) and limited competition for oseltamivir powder (generic version of Tamiflu). After the Moraiya (Ahmedabad) plant was successfully re-inspected in fiscal 2018, abbreviated new drug application (ANDA) approvals surged to 77 ' the company's highest-ever annual approvals. Out of more than 50 products to be launched in the US in fiscal 2019, around 10 have been rolled out in the first quarter. The US segment is likely to benefit from these product launches and support steady revenue growth of 9-10% in the near to medium term. Regular product launches will help offset the intensifying pricing pressure in the US.  Diversity in revenue through the Zydus Cadila group's established presence in semi-regulated markets, animal healthcare formulations and consumer wellness products, will continue to support the business risk profile.

Operating margin is expected to remain healthy around 20% in the medium term, while research and development (R&D) expenses may continue at around 7-8% of sales. However, sustained momentum of ANDA filings, approvals, and launches in regulated markets will be critical for profitability to sustain. Steady operating margin, coupled with a strong US product pipeline, leadership position in domestic business and presence in other diverse segments, is expected to improve net cash accrual significantly to over Rs 2,000 crore annually, from about Rs 1,400-1,500 crore, earlier.

Annual capital expenditure (capex) plans of Rs 800-1000 crore can be funded through internal accrual. Backed by healthy cash generation and in the absence of any large debt-funded capex/ acquisition, the gearing is expected to improve to about 0.5 time in the medium term (0.7 time as on March 31, 2018). Debt/EBITDA (earnings before interest, tax, depreciation and amortisation) is also expected to strengthen to around 1.5-1.6 times (1.90 time as on March 31, 2018). Besides, the company had liquid surplus of around Rs 1,600 crore as on March 31, 2018. However, any large debt-funded acquisition, exerting pressure on gearing, will remain a key rating sensitivity factor.

Analytical Approach

For arriving at the ratings of Cadila Healthcare, CRISIL has combined the business and financial risk profiles of Cadila Healthcare Ltd, and its 35 subsidiaries and step-down subsidiaries (referred as the Zydus Cadila group), as all entities operate in the pharmaceutical and related space, with significant operational linkages, under a common management. For equal joint ventures (JV), CRISIL follows a moderate integration approach; specifically, CRISIL factors in share of profit from JVs, and share of any incremental investments required by JVs. CRISIL has amortised goodwill on consolidation, over five years. Both profit after tax and networth are adjusted to that extent.

Key Rating Drivers & Detailed Description
Strengths
* Established position in the branded generics market: The Zydus Cadila group is one of the top five players in the domestic formulations market, valued at over Rs 1,00,000 crore. Domestic formulations accounted for 29% of revenue in fiscal 2018, and has been in the range of 30-40%. However, higher revenue from the US segment and moderation in domestic growth has reduced the revenue share of domestic formulations from 34% a year before. 

The group is the market leader in the high-growth lifestyle segments such as gastrointestinal, cardiology, respiratory and gynaecology, which account for over 40% of its domestic formulation sales. As of March 31, 2018, 16 of the Zydus Cadila group's brands rank among the country's top 300 pharmaceutical brands. Growth has been subdued in the recent past, due to intense competition in key therapies, personnel related challenges, price revisions and destocking by chemists, in anticipation of goods and service tax (GST) implementation. To address these challenges, the group has strengthened its marketing team, and has moved its domestic base to Mumbai from Ahmedabad. This is expected to improve its growth momentum in the medium term, also given the established brands, a large and therapeutic-focused field force, in-licensing agreements, and product launches. Domestic segment grew 40% in the first quarter of fiscal 2019, reflecting recovery from GST impact in the corresponding quarter of previous fiscal. It also has established presence in other rest of the world markets of Brazil, Mexico and South Africa.

* Growing presence in the regulated generics markets: The group's business prospects are supported by growing presence in regulated generics markets like the US. The group filed 26 ANDAs, taking its tally of ANDA filings of 330, of which 186 have been approved, as on March 31, 2018. The healthy pace of filings and approvals in the US, also reflected in the strong ANDA pipeline of over 140 as of March 2018, will strengthen the US business. With formulation revenue of Rs 5,835 crore in fiscal 2018, the group is one of the top 10 players in the US generic market (Source: IMS Moving Annual Total, March 2018).

* Healthy financial risk profile: Financial risk profile is marked by a comfortable capital structure and sound debt protection metrics. Adjusted gearing and net gearing stood at 0.70 and 0.49 time, respectively, as on March 31, 2018, vis-Ã''' -vis 0.86 and 0.60 time, a year before. The group's interest coverage ratio stood at 33 times as of fiscal 2018. Unencumbered cash and cash equivalents of around Rs 1,600 crore were reported as on March 31, 2018. Healthy cash accrual, notwithstanding any moderate capex plans, is expected to further improve the financial risk profile.

Weaknesses
* Exposure to risks related to unfavourable regulatory changes: The Zydus Cadila group remains exposed to regulatory risks, both in domestic and international markets, particularly the US. While the Moraiya plant was successfully re-inspected and ANDA approvals have been received, the group continues to face heightened regulatory scrutiny. For instance, in fiscal 2017, revenue growth was negative in the US market because of drop in approvals and launches. Similarly, in the domestic market, drugs under acute as well as chronic therapies were added to the National List of Essential Medicines regularly in 2017. And in fiscal 2018, destocking by chemists in anticipation of GST affected growth (in the domestic formulations segment) during the first quarter. Consequently, the domestic segment posted slower single-digit growth in fiscals 2018 and 2017. Government's ban on fixed drug combinations is unlikely to have any major impact on the Zydus Cadila group.

* Exposure to intense competition, volatility in foreign exchange rates and stretch in the working capital cycle: The Zydus Cadila group faces intense competition in regulated markets, which is marked by aggressive defence tactics by innovator companies through introduction of authorised generics, and presence of several cost-competitive Indian players. Furthermore, generics players in regulated markets are affected by severe price erosions, given the commoditised nature of products, along with intense competition and considerable government pressure to lower prices. Strong bargaining power of distributors in the US, leads to high working capital intensity. The group's gross current assets (net of liquid surplus) have increased by 40-50 days over past three fiscals to around 200 days for fiscal 2018. Ample liquidity and high financial flexibility is expected to meet the incremental working capital requirement.
Outlook: Positive

CRISIL expects Cadila Healthcare's business risk profile to strengthen in the medium term, backed by its strong pipeline in the US and diversified revenue profile. The financial risk profile is expected to remain healthy, with above-average networth, adequate gearing, and moderate sized debt-funded capex plans.

Upward scenario
* Increased revenue contribution from the US market, led by healthy pipeline and product approvals
* Alternatively, significant and sustained increase in revenue from other markets
* Sustenance of profitability and improvement in financial risk profile

Downward scenario
* Decline in operating profitability to below 18%, most likely due to increased competition or regulatory issues
* Significant weakening of capital structure because of large, debt-funded capex or acquisitions, and/or material elongation in working capital cycle.

About the Company

Cadila Laboratories Ltd (Cadila Laboratories) was founded in 1952 by Mr Ramanbhai Patel and Mr Indravadan Modi. Cadila Healthcare came into existence in 1995 following the split of Cadila Laboratories, with the Modi family's share being moved into a new company called Cadila Pharmaceuticals Ltd. The division that was managed by Mr Ramanbhai Patel's son, Mr Pankaj Patel, was renamed Cadila Healthcare Ltd, and the group was named Zydus Cadila. In 2000, Cadila Healthcare got listed on the Bombay Stock Exchange. As on June 30, 2018, the promoters held 74.79% stake in Cadila Healthcare, foreign portfolio investors held 8.73%, and the balance was held by the public and others. Over the years, the company has grown to become one of the top five pharmaceutical companies in India.

For the quarter ended June 30, 2018, the Zydus Cadila group reported a profit after tax (PAT) of Rs 467 crore (PAT of Rs 145 crore for the quarter ended June 30, 2017), on operating income of Rs 2,894 crore (Rs 2,185 crore for the quarter ended June 30, 2017).

Key Financial Indicators
Particulars Unit 2018 2017
Revenue (net of excise) Rs crore 11,887 9,357
Adjusted Profit after tax (PAT)* Rs crore 1,585 1,404
Adjusted PAT margin* % 13.3 14.9
Adjusted debt/adjusted networth* Times 0.70 0.86
Interest coverage Times 33 45
*Adjusted for goodwill and intangibles amortisation

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon Rate (%) Maturity Date Issue Size
(Rs. Cr)
Rating Assigned
with Outlook
NA Bank guarantee NA NA NA 50 CRISIL A1+
NA Letter of credit NA NA NA 100 CRISIL A1+
NA Cash credit* NA NA NA 1300 CRISIL AA+/Positive
NA Long Term Loan NA NA 27-Dec-2018 45.64 CRISIL AA+/Positive
NA Long Term Loan NA NA 20-Mar-2020 86.91 CRISIL AA+/Positive
NA Long Term Loan NA NA 17-Jan-2022 195.60 CRISIL AA+/Positive
NA Long Term Loan NA NA 27-Mar-2023 652 CRISIL AA+/Positive
NA Long Term Loan@ NA NA 10-July 2018 130.40 CRISIL AA+/Positive
NA Long Term Loan NA NA 18-Sep-23 130.62 CRISIL AA+/Positive
NA Long term loan NA NA 01-Mar-22 130.4 CRISIL AA+/Positive
NA Long term loan NA NA 26-Apr-2023 195.60 CRISIL AA+/Positive
NA Proposed Long Term Bank Loan Facility NA NA NA 559.83 CRISIL AA+/Positive
NA Commercial Paper& NA NA 7-365 days 250.00 CRISIL A1+
NA Non Convertible Debentures** NA NA NA 75.00 CRISIL AA+/Positive
NA Non Convertible Debentures** NA NA NA 50.00 CRISIL AA+/Positive
*Fully interchangeable with Working capital demand loan and Packing credit in Foreign Currency
**Yet to be issued;
@Withdrawal document awaited
&Earlier STD (Including CP)
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Commercial Paper  ST  250.00  CRISIL A1+  29-06-18  CRISIL A1+  13-06-17  CRISIL A1+  01-11-16  CRISIL A1+  21-09-15  CRISIL A1+   CRISIL A1+
            27-01-17 CRISIL A1+           
Non Convertible Debentures  LT  0.00
20-09-18 
CRISIL AA+/Positive  29-06-18  CRISIL AA+/Positive  13-06-17  CRISIL AA+/Stable  01-11-16  CRISIL AA+/Stable  21-09-15  CRISIL AA+/Stable  CRISIL AA+/Stable 
            27-01-17  CRISIL AA+/Stable           
Fund-based Bank Facilities  LT/ST  3427.00  CRISIL AA+/Positive  29-06-18  CRISIL AA+/Positive  13-06-17  CRISIL AA+/Stable  01-11-16  CRISIL AA+/Stable  21-09-15  CRISIL AA+/Stable  CRISIL AA+/Stable 
            27-01-17  CRISIL AA+/Stable           
Non Fund-based Bank Facilities  LT/ST  150.00  CRISIL A1+  29-06-18  CRISIL A1+  13-06-17  CRISIL A1+  01-11-16  CRISIL A1+  21-09-15  CRISIL A1+  CRISIL A1+ 
            27-01-17  CRISIL A1+           
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 50 CRISIL A1+ Bank Guarantee 50 CRISIL A1+
Cash Credit* 1300 CRISIL AA+/Positive Cash Credit* 1300 CRISIL AA+/Positive
Letter of Credit 100 CRISIL A1+ Letter of Credit 100 CRISIL A1+
Long Term Loan 1567.17 CRISIL AA+/Positive Long Term Loan 1567.17 CRISIL AA+/Positive
Proposed Long Term Bank Loan Facility 559.83 CRISIL AA+/Positive Proposed Long Term Bank Loan Facility 559.83 CRISIL AA+/Positive
Total 3577 -- Total 3577 --
*Fully interchangeable with Working capital demand loan and Packing credit in Foreign Currency
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Bank Loan Ratings
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Sameer Charania
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8025
sameer.charania@crisil.com


Varsha Chandwani
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3163
Varsha.Chandwani@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL